RBC Capital analyst Nik Modi keeps a Sector Perform rating on Kenvue (KVUE) after the Wall Street Journal reported Health Secretary Robert F. Kennedy Jr. plans to claim in a report this month that low levels of folate and Tylenol taken during pregnancy are potential causes of autism. Kenvue’s Self Care unit, which includes Tylenol, had fiscal 2024 sales of $15.5B, underscoring its importance, the analyst tells investors in a research note. However, RBC says the scientific link between acetaminophen and autism remains unproven in court and that Kenvue has successfully defended against association, not causation, in the majority of federal cases to date. Shares of Kenvue are down 14% to $17.64 in afternoon trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue extends selloff after WSJ report, shares down 16% to $17.33
- Kenvue sees ‘no causal link’ between acetaminophen use in pregnancy and autism
- RFK Jr. to claim autism link to Tylenol use in pregnancy, WSJ reports
- Kenvue drops 9% to $18.74 after WSJ report
- Kenvue sinks after WSJ says RFK to link autism to Tylenol use